| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 28 Jan 2025 | 21 Jan 2025 |
| BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2024; and The proposal for issuance of Sweat Equity Shares pursuant to applicable provisions of the Companies Act 2013 the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations 2021 and other applicable laws and regulations to Key Managerial Personnel and/or Senior Management Personnel and/or Employee(s) of the Company including determination of the issue price if any subject to such regulatory and statutory approvals as may be required including approval of the shareholders of the Company. Please find the attached Outcome of Board Meeting held on Tuesday, January 28, 2025. (As Per Bse Announcement Dated on 28.01.2025) | ||
| Board Meeting | 24 Oct 2024 | 17 Oct 2024 |
| BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half yearly ended September 30 2024 Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half yearly ended September 30 2024 Please find the attached Outcome of Board Meeting held on Thursday, October 24, 2024. (As per BSE Announcement Dated on 24/10/2024) | ||
| Board Meeting | 24 Jul 2024 | 17 Jul 2024 |
| BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2024. Further according to SEBI (Prohibition of Insider Trading) Regulations 2015 and the Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from July 01 2024 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Financial Results of the Company for the quarter ended June 30 2024. Please find attached herewith the Outome of Board Meeting held on today i.e. July 24, 2024 for approval of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2024. (As per BSE Announcement Dated on 24/07/2024) | ||
| Board Meeting | 2 May 2024 | 25 Apr 2024 |
| BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 inter alia to consider and approve a) To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31 2024 along with the Statement of Assets and Liabilities Cash Flow Statement and take note of the Audit Report with modified opinion if any thereon; b) To consider and approve the Audited Standalone and Consolidated Financial Statement of the Company for the financial year ended March 31 2024; and c) To discuss and recommend the Final Dividend if any for the financial year ended March 31 2024. We would like to inform you that, the Board Meeting of the Company was held today i.e. Thursday, May 02, 2024 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the matters amongst others as attached. Please find attached herewith Outcome of the Board Meeting held on May 02, 2024. Recommended Final Dividend of 50% i.e. 50 Paisa per equity share on the face value of Rs. 1/- each for the financial year ended March 31, 2024, subject to the approval of the shareholders in the forthcoming 39th Annual General Meeting of the Company. (As Per BSE Announcement Dated on 02.05.2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
